Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Colorectal Neoplasms 2Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Leiomyosarcoma 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

Sorafenib 22Bevacizumab 15pembrolizumab 10durvalumab 7Nivolumab 7Ipilimumab 6Drug Therapy 6atezolizumab 5Talaporfin 5spartalizumab 4regorafenib 4lenvatinib 4derazantinib 3Ramucirumab 3Photochemotherapy 3Leucovorin 3Injections 3Fluorouracil 3Doxorubicin 3tremelimumab 2toripalimab 2seocalcitol 2relatlimab 2phosphomannopentaose sulfate 2liposomal doxorubicin 2exatecan 2cabozantinib 2brivanib 2Phototherapy 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Liver Neoplasms × cixutumumab × Clear all
NCT00906373 2018-06-04

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

Eli Lilly and Company

Phase 2 Completed
47 enrolled 14 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡